Exercise of warrants

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, announces that the Company has received a notice to exercise warrants over 20,000,000 new ordinary shares of £0.001 each in the Company (the "Warrant Shares") at an exercise price of £0.001 per Warrant Share, raising £20,000 of new funds for the Company.

Admission and Total Voting Rights

Application will be made for the Warrant Shares to be admitted to trading on the Main Market of the London Stock Exchange and to listing in the FCA's Official List Equity Shares (transition) category ("Admission"). It is expected that Admission will become effective at 8.00 a.m. on or around 24 July 2025.

Following Admission, the Company's issued ordinary share capital will comprise 6,262,104,024 ordinary shares of £0.001 each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.